Hospital
ST Lukes Nampa Medical Center LTD
ST Lukes Nampa Medical Center LTD was paid $1.87M by Medicaid between Jan 2018 and Dec 2024, across 175 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 14% of everything it billed.
33Billing provider infoST LUKES NAMPA MEDICAL CENTER LTD
NAMPA, ID 83687
NAMPA, ID 83687
33aNPI1831590660assigned 09/11/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.87M
24GClaims179,599
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Idaho
Rank by total paid#8 of 12
Median peer was paid$3.12M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FOWLER, KATHRYN controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,960 | $577K | |
| 2019 | 59,577 | $647K | |
| 2020 | 34,905 | $479K | |
| 2021 | 6,352 | $35K | |
| 2022 | 8,905 | $54K | |
| 2023 | 8,037 | $53K | |
| 2024incomplete | 4,863 | $21K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 14% | 2,046 | 1,950 | $258K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.8% | 6,744 | 5,814 | $127K |
| 80053 | Comprehensive metabolic panel | 4.9% | 13,744 | 12,016 | $91K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.5% | 17,154 | 14,524 | $85K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.9% | 1,541 | 1,378 | $73K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.2% | 822 | 773 | $60K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.2% | 1,740 | 1,564 | $59K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 1,466 | 550 | $49K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 1,198 | 1,154 | $47K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.4% | 429 | 417 | $45K |
| 71046 | Radiologic examination, chest; 2 views | 2.3% | 3,237 | 3,131 | $42K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.2% | 2,246 | 2,169 | $41K |
163 more codes
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 2.0% | 894 | $37K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 502 | $33K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.8% | 256 | $33K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 1,595 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 2,054 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 350 | $25K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 746 | $23K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 1,654 | $23K |
| 83690 | 1.2% | 4,599 | $22K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 3,201 | $19K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,957 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 909 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 522 | $18K |
| 84484 | <1% | 3,547 | $18K | |
| 81001 | <1% | 7,788 | $18K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 499 | $17K |
| 76770 | <1% | 336 | $17K | |
| 81025 | <1% | 2,487 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,985 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,035 | $15K |
| 76830 | Ultrasound, transvaginal | <1% | 229 | $15K |
| 83880 | <1% | 740 | $14K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 365 | $13K |
| 83605 | <1% | 1,863 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 436 | $13K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 170 | $12K |
| 99285 | Emergency room visit (most serious) | <1% | 154 | $12K |
| 80061 | Lipid panel | <1% | 1,223 | $12K |
| 74018 | <1% | 913 | $12K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 125 | $10K |
| 70496 | <1% | 84 | $10K | |
| 87420 | <1% | 750 | $10K | |
| 87040 | <1% | 1,049 | $10K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 580 | $10K |
| 83970 | <1% | 409 | $10K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 105 | $9K |
| 87077 | <1% | 1,168 | $9K | |
| 84439 | <1% | 1,081 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,811 | $9K |
| 84702 | <1% | 599 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,371 | $8K |
| 80306 | <1% | 570 | $8K | |
| 85379 | <1% | 860 | $7K | |
| 73610 | <1% | 440 | $7K | |
| 70498 | <1% | 56 | $7K | |
| 73564 | <1% | 372 | $7K | |
| 87081 | <1% | 922 | $6K | |
| 86140 | <1% | 1,502 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,260 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,422 | $6K |
| 82962 | <1% | 2,175 | $6K | |
| 87186 | <1% | 789 | $6K | |
| 73630 | <1% | 396 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 537 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 102 | $5K |
| 73110 | <1% | 256 | $5K | |
| 82728 | <1% | 450 | $4K | |
| 85610 | <1% | 1,881 | $4K | |
| 81003 | <1% | 2,070 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 85 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 396 | $4K |
| 83735 | <1% | 1,293 | $4K | |
| 76642 | <1% | 111 | $4K | |
| 97162 | <1% | 70 | $3K | |
| 72141 | <1% | 26 | $3K | |
| 80069 | <1% | 512 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,946 | $3K |
| 87641 | <1% | 85 | $3K | |
| 87640 | <1% | 85 | $3K | |
| 73130 | <1% | 150 | $2K | |
| 84703 | <1% | 308 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 58 | $2K |
| 73030 | <1% | 171 | $2K | |
| 83540 | <1% | 505 | $2K | |
| 83550 | <1% | 360 | $2K | |
| 82570 | <1% | 725 | $2K | |
| 36416 | <1% | 698 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 27 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 39 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,399 | $2K |
| 85652 | <1% | 923 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,229 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,425 | $2K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $2K |
| 82803 | <1% | 98 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 789 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 807 | $2K |
| 85730 | <1% | 359 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $2K |
| 72100 | <1% | 107 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 723 | $1K |
| 84100 | <1% | 868 | $1K | |
| 86901 | <1% | 476 | $1K | |
| 80197 | <1% | 589 | $1K | |
| 82607 | <1% | 114 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 584 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 706 | $1K |
| 73080 | <1% | 76 | $1K | |
| 87210 | <1% | 275 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 402 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 72 | $1K |
| 73502 | <1% | 70 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 29 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 928 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,810 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,240 | $869.64 |
| 71250 | <1% | 14 | $790.95 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 89 | $740.82 |
| 83516 | <1% | 64 | $703.50 | |
| 70486 | <1% | 12 | $640.87 | |
| 73140 | <1% | 37 | $636.14 | |
| 84156 | <1% | 329 | $615.02 | |
| 87070 | <1% | 72 | $586.79 | |
| 73090 | <1% | 43 | $578.07 | |
| 82746 | <1% | 52 | $574.63 | |
| 84481 | <1% | 38 | $567.43 | |
| 82565 | <1% | 112 | $561.41 | |
| 87205 | <1% | 146 | $531.34 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 97 | $530.61 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $517.53 |
| 82550 | <1% | 121 | $513.36 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,666 | $510.78 |
| 82784 | <1% | 41 | $495.83 | |
| 80076 | <1% | 73 | $489.62 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $485.03 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,319 | $451.80 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 448 | $442.26 |
| 86850 | <1% | 58 | $435.24 | |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $412.77 |
| 81002 | <1% | 148 | $389.63 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 433 | $346.35 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 31 | $343.56 |
| 83525 | <1% | 26 | $330.19 | |
| 86803 | <1% | 25 | $317.00 | |
| 77080 | <1% | 58 | $305.62 | |
| 86900 | <1% | 116 | $304.77 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 32 | $279.53 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 960 | $255.06 |
| 90715 | <1% | 13 | $250.76 | |
| 72040 | <1% | 15 | $248.91 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 323 | $245.99 |
| 84550 | <1% | 85 | $236.49 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14 | $212.19 |
| 82010 | <1% | 26 | $181.60 | |
| 73590 | <1% | 14 | $165.30 | |
| 82043 | <1% | 70 | $164.99 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 143 | $129.70 |
| G0008 | Administration of influenza virus vaccine | <1% | 67 | $116.29 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 30 | $73.03 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 121 | $69.37 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 107 | $66.85 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 39 | $50.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 57 | $48.46 |
| 90656 | <1% | 21 | $17.81 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19 | $13.52 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 30 | $8.00 |
| 80050 | General health panel | <1% | 60 | $7.64 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 13 | $1.56 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 1,151 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,085 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 28 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOWLER, KATHRYN (SENIOR VP, CFO)
Parent organizationST LUKES HEALTH SYSTEM LTD
| Provider | Location | Paid |
|---|---|---|
| ST Lukes Clinic-Treasure Valley LLC | Boise, ID | $59.26M |
| ST Luke's Clinic LLC | Twin Falls, ID | $39.50M |
| ST Lukes Regional Medical Center | Boise, ID | $24.98M |
| ST. Luke's Magic Valley Regional Medical Center, LTD. | Twin Falls, ID | $7.95M |
| ST Lukes Clinic-Treasure Valley LLC | Mountain Home, ID | $6.86M |
| Magic Valley Paramedics L L C | Twin Falls, ID | $4.57M |
| ST Lukes Clinic-Treasure Valley LLC | Baker City, OR | $2.08M |
| ST Luke's Regional Medical Center | Meridian, ID | $1.55M |
| ST Lukes Regional Medical Center | Mountain Home, ID | $942K |
| ST Lukes Clinic - Wood River LLC | Ketchum, ID | $717K |
| ST Luke's Magic Valley Regional Medical Center LTD | Jerome, ID | $577K |
| ST Lukes Clinic - Mccall LLC | Mccall, ID | $576K |
| ST Luke's Regional Medical Center | Meridian, ID | $397K |
| ST. Luke's Magic Valley Regional Medical Center LTD | Twin Falls, ID | $300K |
| ST Lukes Wood River Medical Center LTD | Ketchum, ID | $174K |
| ST Lukes Mccall LTD | Mccall, ID | $149K |
| ST Lukes Regional Medical Center | Boise, ID | $49K |
| ST Lukes Magic Valley Regional Medical Center LTD | Twin Falls, ID | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.